1. Home
  2. PCF vs ADVM Comparison

PCF vs ADVM Comparison

Compare PCF & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo High Income Securities Fund

PCF

High Income Securities Fund

HOLD

Current Price

$6.11

Market Cap

116.4M

Sector

Finance

ML Signal

HOLD

Logo Adverum Biotechnologies Inc.

ADVM

Adverum Biotechnologies Inc.

HOLD

Current Price

$4.36

Market Cap

94.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCF
ADVM
Founded
1987
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.4M
94.6M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
PCF
ADVM
Price
$6.11
$4.36
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$11.60
AVG Volume (30 Days)
74.8K
497.5K
Earning Date
01-01-0001
11-12-2025
Dividend Yield
10.90%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1,192.00
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.71
$1.78
52 Week High
$6.96
$6.12

Technical Indicators

Market Signals
Indicator
PCF
ADVM
Relative Strength Index (RSI) 34.76 58.20
Support Level $6.23 $4.15
Resistance Level $6.28 $4.23
Average True Range (ATR) 0.04 0.09
MACD -0.00 0.02
Stochastic Oscillator 10.53 95.22

Price Performance

Historical Comparison
PCF
ADVM

About PCF High Income Securities Fund

High Income Securities Fund is a closed-end management investment company. Its primary objective is to provide high current income and capital appreciation is the secondary objective. The Fund pursues its objective mainly by investing in both convertible bonds and convertible preferred stocks. The Fund also invests significantly in high-yielding non-convertible securities with the potential for capital appreciation.

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

Share on Social Networks: